Modalis Therapeutics Corporation
|
| Code |
Sector |
Market |
Lead Underwriter |
Date of listing approval |
IPO Date |
| 4883 |
Pharmaceuticals |
MTH |
Mizuho |
2020/06/26 |
2020/08/03 |
| 【Description】 |
| Research and development of gene therapy drugs using the core platform technology "Incisive CRISPR technology (CRISPR-GNDM technology)" |
IPO Information |
| Opening Price |
Y2,520 |
Total Amount |
Y3,726,000,000 |
| IPO Price |
Y1,200 |
--Company |
Y2,318,400,000 |
Aggregate Value
(based on Initial Price) |
68,544
(Unit:1 million) |
--Leading Shareholder |
Y1,109,520,000 |
| Listed Shares(total) |
3,105,000 |
--Lead Manager |
Y298,080,000 |
| Trading Unit |
100 |
|
Offering Price PER
(based on previous period) |
201.34 |
Offering Price PBR
(based on previous period) |
7.84 |
| Initial Price PER |
422.82 |
Initial Price PBR |
16.46 |
| New Shares |
2,100,000 |
Existing Shares |
1,005,000（incl. O.A.） |
| Shares Outstanding |
Pre IPO |
25,100,000.00 |
PostIPO |
27,200,000.00 |
| Paid Up Capital |
PreIPO |
Y1,300,000,000 |
PostIPO |
Y2,075,008,000 |
| Use of Funds Raised |
|
Financial Data |
| Units:Y1,000 |
| Fiscal Year End |
|
Revenue |
Current Profit |
Net Profit |
Net Assets |
| 2017/12 |
Consolidated |
- |
- |
- |
- |
| Non-consolidated |
17,921 |
-141,200 |
-142,150 |
1,421,735 |
| 2018/12 |
Consolidated |
65,297 |
-213,390 |
-217,909 |
1,201,779 |
| Non-consolidated |
65,297 |
-228,981 |
-229,932 |
1,191,802 |
| 2019/12 |
Consolidated |
644,500 |
146,351 |
140,528 |
3,842,542 |
| Non-consolidated |
644,500 |
128,822 |
127,899 |
3,819,701 |
Recent Quarter
2020/03 |
Consolidated |
13,000 |
-116,924 |
-118,286 |
3,724,455 |
| Non-consolidated |
- |
- |
- |
- |
| Per Share |
Units:Y1 |
| Fiscal Year End |
|
Dividend |
Net Earning |
Equity |
|
| 2017/12 |
Consolidated |
0.00 |
- |
- |
|
| Non-consolidated |
-10.29 |
-3.89 |
|
| 2018/12 |
Consolidated |
0.00 |
-10.84 |
-14.84 |
|
| Non-consolidated |
-11.44 |
-15.33 |
|
| 2019/12 |
Consolidated |
0.00 |
5.96 |
153.09 |
|
| Non-consolidated |
5.43 |
152.18 |
|
| Fiscal Year End |
|
Dividend |
Net Earning |
Equity |
|
Recent Quarter
2020/03 |
Consolidated |
|
-4.71 |
- |
|
| Non-consolidated |
- |
- |
|
Comment |
| ■Over allotment(405,000) |
| Consolidated Subsidiaries |
| Name |
Address |
| Underwriters |
| Allocation |
Underwriter |
Tel |
| 75% |
Mizuho |
03-5208-3210 |
| 11% |
SBI SECURITIES Co.,Ltd. |
03-5562-7210 |
| 11% |
SMBC Nikko |
03-5644-3111 |
| 1.5% |
Ichiyoshi |
03-3555-6210 |
| 1.5% |
Ace |
06-6267-2111 |
| Data |
| Date of incorporation |
2016/01/14 |
| Company address |
Tokyo 103-0026 |
| Telephone |
03-6822-4584 |
| President |
|
| Homepage |
https://www.modalistx.com/jp/ |
| Auditor |
Azsa |
|
|
| Major Shareholders |
| Shareholder Name |
Ratio |
| |
17.86% |
| |
16.07% |
| |
8.39% |
| |
8.39% |
| |
3.75% |
| |
3.57% |
| |
2.86% |
| |
2.68% |
| |
2.68% |
| |
2.59% |
| Number of Employees |
3 as of 2020/05/31 |
| Birth Date of Representative |
1969/08/09 |
|
|
IPO最新情報、セミナー・イベント情報などをタイムリーにお届けします。
|
|
IPO関連ニュースをTwitterでも掲載中。初値予想アンケートも実施中です！
|
|
今後の躍進が期待される注目銘柄のアナリストレポートをご覧いただけます。
|
|
個人投資家向けIRセミナーを開催しませんか？開催希望企業募集中！
|
|
